Oxidative Stress Levels, JAK2V617F Mutational Status and Thrombotic Complications in Patients with Essential Thrombocythemia

被引:0
|
作者
Moisa, Cornel [1 ]
Gaman, Mihnea Alexandru [2 ]
Diaconu, Camelia Cristina [2 ,3 ]
Gaman, Amelia Maria [4 ,5 ]
机构
[1] Cty Emergency Hosp Slatina, Dept Haematol, 5 Crisan Str, Slatina 230008, Romania
[2] Carol Davila Univ Med & Pharm, 8 Eroii Sanit Blvd, Bucharest 050474, Romania
[3] Clin Emergency Hosp Bucharest, Internal Med Clin, 8 Calea Floreasca Str, Bucharest 014461, Romania
[4] Univ Med & Pharm Craiova, Dept Pathophysiol, 2 Petru Rares Str, Craiova 200349, Romania
[5] Filantropia City Hosp, Clin Haematol, 1 Filantropiei Str, Craiova 200143, Romania
来源
REVISTA DE CHIMIE | 2019年 / 70卷 / 08期
关键词
essential thrombocythemia; reactive oxygen species; total antioxidant capacity; JAK2V617F; thrombosis; TYROSINE KINASE JAK2; POLYCYTHEMIA-VERA; CALRETICULIN; ACTIVATION; PLATELET; INFLAMMATION; IMPACT; MPL;
D O I
暂无
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Essential thrombocythemia (ET) is a BCR-ABL1-negative myeloproliferative neoplasm associated with thrombotic and haemorrhagic complications. Reactive oxygen species (ROS) overexpression induces a growth advantage to JAK2V617F-positive clones and, in association with a higher number of immature platelets, leukocytosis, and additional cardiovascular risk factors, leads to an increased risk for thrombotic events. We evaluated oxidative stress by measuring ROS levels and the total antioxidant capacity (TAC) in 62 ET patients and investigated the relationship between oxidative stress, JAK2V617F mutational status and the development of thrombotic events. We found higher oxidative stress levels in JAK2V617F-positive vs. JAK2V617F-negative ET cases with no significant differences between homozygous and heterozygous genotypes. Increased ROS levels and thrombotic events were more frequent in ET patients with old age at diagnosis, higher haematocrit levels or leukocytosis.
引用
收藏
页码:2822 / 2825
页数:4
相关论文
共 50 条
  • [31] Platelet function studies in myeloproliferative neoplasms patients with Calreticulin or JAK2V617F mutation
    Guy, Alexandre
    Helzy, Khalil
    Mansier, Olivier
    Bordet, Jean-Claude
    Riviere, Etienne
    Fiore, Mathieu
    James, Chloe
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2023, 7 (02)
  • [32] JAK2V617F mutation in platelets from essential thrombocythemia patients:: correlation with clinical features and analysis of STAT5 phosphorylation status
    Heller, Paula G.
    Lev, Paola R.
    Salim, Juan P.
    Kornblihtt, Laura I.
    Goette, Nora P.
    Chazarreta, Carlos D.
    Glembotsky, Ana C.
    Vassallu, Patricia S.
    Marta, Rosana F.
    Molinas, Felisa C.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2006, 77 (03) : 210 - 216
  • [33] Impact of CALR and JAK2V617F Mutations on Clinical Course and Disease Outcomes in Essential Thrombocythemia: A Multicenter Retrospective Study in Turkish Patients
    Ozdemir, Zehra Narli
    Ipek, Yildiz
    Patir, Puesem
    Ermis, Goezde
    Ciftciler, Rafiye
    Ozmen, Deniz
    Baysal, Mehmet
    Gursoy, Vildan
    Yildizhan, Esra
    Guven, Serkan
    Ercan, Tarik
    Elibol, Tayfun
    Mersin, Sinan
    Genc, Eylem
    Davulcu, Eren Arslan
    Karakus, Volkan
    Erkut, Nergiz
    Gunes, Guersel
    Kucukkaya, Reyhan Diz
    Eskazan, Ahmet Emre
    TURKISH JOURNAL OF HEMATOLOGY, 2024, 41 (01) : 26 - 36
  • [34] Coexistence of JAK2V617F Mutation and BCR-ABL Translocation in a Pregnant Woman with Essential Thrombocythemia
    Qin, You-wen
    Yang, Yi-ning
    Li, Su
    Wang, Chun
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2014, 30 : S331 - S334
  • [35] JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia
    Hobbs, Catherine M.
    Manning, Harriet
    Bennett, Cavan
    Vasquez, Louella
    Severin, Sonia
    Brain, Lauren
    Mazharian, Alexandra
    Guerrero, Jose A.
    Li, Juan
    Soranzo, Nicole
    Green, Anthony R.
    Watson, Steve P.
    Ghevaert, Cedric
    BLOOD, 2013, 122 (23) : 3787 - 3797
  • [36] Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status
    Finazzi, Guido
    Rambaldi, Alessandro
    Guerini, Vittoria
    Carobbo, Alessandra
    Barbui, Tiziano
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (01): : 135 - 136
  • [37] The impact of JAK2V617F mutation on different types of thrombosis risk in patients with essential thrombocythemia: a meta-analysis
    Youwen Qin
    Xiaorui Wang
    Chuxian Zhao
    Chun Wang
    Yining Yang
    International Journal of Hematology, 2015, 102 : 170 - 180
  • [38] Identification of the Key Genes and Molecular Pathways in Essential Thrombocythemia Associated with JAK2V617F Mutation Using Bioinformatics Approach
    Elbager, Sahar Gamal
    Dowd, Amar A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S360 - S361
  • [39] Pronounced gut microbiota signatures in patients with JAK2V617F-positive essential thrombocythemia
    Eickhardt-Dalbge, Christina Schjellerup
    Ingham, Anna Cacilia
    Nielsen, Henrik V.
    Fuursted, Kurt
    Stensvold, Christen Rune
    Andersen, Lee O'Brien
    Larsen, Morten Kranker
    Kjaer, Lasse
    Christensen, Sarah Friis
    Knudsen, Trine Alma
    Skov, Vibe
    Ellervik, Christina
    Olsen, Lars Rnn
    Hasselbalch, Hans Carl
    Elmer Christensen, Jens Jrgen
    Nielsen, Xiaohui Chen
    MICROBIOLOGY SPECTRUM, 2023, 11 (05):
  • [40] JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis
    Guglielmelli, Paola
    Barosi, Giovanni
    Pieri, Lisa
    Antonioli, Elisabetta
    Bosi, Alberto
    Vannucchi, Alessandro M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (01): : 144 - 146